Company Description
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction.
It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot"Marie"Tooth Association.
The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
| Country | Switzerland |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Timothy Mark Dyer |
Contact Details
Address: Chemin Des Mines 9 Geneva, V8 CH-1202 Switzerland | |
| Phone | 01141228841555 |
| Website | addextherapeutics.com |
Stock Details
| Ticker Symbol | ADXN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001574232 |
| CUSIP Number | 00654J107 |
| ISIN Number | US00654J2069 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Timothy Mark Dyer | Co-Founder, Chief Executive Officer and Director |
| Dr. Roger G. Mills M.D. | Chief Medical Officer and Director |
| Lénaic Teyssédou | Head of Finance |
| Dr. Jean-Philippe Rocher Ph.D. | Head of Discovery - Chemistry |
| Dr. Robert Lutjens | Head of Discovery - Biology |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 18, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 18, 2024 | 6-K | Report of foreign issuer |
| Apr 3, 2024 | 6-K | Report of foreign issuer |
| Jan 30, 2024 | 424B5 | Filing |
| Jan 30, 2024 | 6-K | Report of foreign issuer |
| Dec 21, 2023 | 6-K/A | Filing |
| Dec 20, 2023 | 6-K | Report of foreign issuer |
| Dec 14, 2023 | 6-K | Report of foreign issuer |
| Dec 8, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |